Logo image of PRFX

PAINREFORM LTD (PRFX) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:PRFX - IL0011651580 - Common Stock

0.6952 USD
+0.02 (+2.61%)
Last: 1/6/2026, 3:08:25 PM

PRFX Key Statistics, Chart & Performance

Key Statistics
Market Cap2.73M
Revenue(TTM)N/A
Net Income(TTM)-14.59M
Shares3.92M
Float3.71M
52 Week High6.65
52 Week Low0.61
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-32.16
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2020-09-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PRFX short term performance overview.The bars show the price performance of PRFX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

PRFX long term performance overview.The bars show the price performance of PRFX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PRFX is 0.6952 USD. In the past month the price decreased by -33.58%. In the past year, price decreased by -78.49%.

PAINREFORM LTD / PRFX Daily stock chart

PRFX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.23 1.00T
JNJ JOHNSON & JOHNSON 19.79 494.93B
MRK MERCK & CO. INC. 12.39 270.85B
PFE PFIZER INC 7.95 144.64B
BMY BRISTOL-MYERS SQUIBB CO 8.33 111.26B
ZTS ZOETIS INC 20.39 56.96B
RPRX ROYALTY PHARMA PLC- CL A 9.85 23.36B
VTRS VIATRIS INC 5.35 14.35B
ELAN ELANCO ANIMAL HEALTH INC 24.59 11.73B
AXSM AXSOME THERAPEUTICS INC N/A 8.60B
BLTE BELITE BIO INC - ADR N/A 5.58B
CRNX CRINETICS PHARMACEUTICALS IN N/A 4.37B

About PRFX

Company Profile

PRFX logo image PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

Company Info

PAINREFORM LTD

65 Yigal Alon St.

TEL AVIV-YAFO 6745442 IL

CEO: Ilan Hadar

Employees: 2

PRFX Company Website

PRFX Investor Relations

Phone: 97237177051

PAINREFORM LTD / PRFX FAQ

What does PAINREFORM LTD do?

PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.


What is the stock price of PAINREFORM LTD today?

The current stock price of PRFX is 0.6952 USD. The price increased by 2.61% in the last trading session.


What is the dividend status of PAINREFORM LTD?

PRFX does not pay a dividend.


What is the ChartMill rating of PAINREFORM LTD stock?

PRFX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Would investing in PAINREFORM LTD be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRFX.


Can you provide the short interest for PRFX stock?

The outstanding short interest for PAINREFORM LTD (PRFX) is 3.28% of its float.


PRFX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PRFX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PRFX. PRFX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRFX Financial Highlights

Over the last trailing twelve months PRFX reported a non-GAAP Earnings per Share(EPS) of -32.16. The EPS increased by 81.23% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -130.69%
ROE -172.78%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%96.15%
Sales Q2Q%N/A
EPS 1Y (TTM)81.23%
Revenue 1Y (TTM)N/A

PRFX Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y38.91%
Revenue Next YearN/A

PRFX Ownership

Ownership
Inst Owners0.42%
Ins OwnersN/A
Short Float %3.28%
Short Ratio0.35